

TABLE OF CONTENT

1. General introduction.....	1
1.1. Multiple sclerosis disease	3
1.1.1. Epidemiology and social impact	3
1.1.2. Primary affected tissues.....	5
1.1.3. Pathophysiology	7
1.1.4. Multiple sclerosis spectrum	9
1.1.5. Diagnosis	12
1.1.6. Treatments	14
1.1.7. Risk factors.....	15
1.1.8. Sex differences.....	16
<i>1.1.8.1. Epidemiology</i>	<i>17</i>
<i>1.1.8.2. Sexual chromosomes</i>	<i>18</i>
<i>1.1.8.3. Sexual hormones</i>	<i>19</i>
<i>1.1.8.4. Focusing on molecular mechanisms</i>	<i>19</i>
1.2. Beyond multiple sclerosis disease: exploring central nervous system disorders.....	20
1.2.1. Alzheimer's disease	22
1.2.2. Parkinson's disease	23
1.2.3. Melanoma	23
1.3. Omics technologies	23
1.3.1. Transcriptomics	24
<i>1.3.1.1. Microarrays</i>	<i>25</i>
<i>1.3.1.2. Bulk RNA-seq</i>	<i>25</i>
<i>1.3.1.3. Single-cell and single nucleus RNA-seq.....</i>	<i>27</i>
1.3.2. Metagenomics	28
1.3.3. Reusing omics data to answer new biological questions.....	30
<i>1.3.3.1. Scientific databases.....</i>	<i>31</i>
<i>1.3.3.2. Systematic review.....</i>	<i>32</i>
<i>1.3.3.3 Meta-analysis</i>	<i>33</i>
2. Motivation and objectives	35
3. STUDY I: Single cell landscape of sex differences in the different courses of multiple sclerosis	39
3.1. Introduction	41

3.1.1. Molecular mechanisms underlying multiple sclerosis in the central nervous system	41
3.1.2. Role of the peripheral immune system in multiple sclerosis	44
3.1.3. Inherent characteristics of single cell transcriptomic data	46
3.1.4. Bioinformatic strategies for analyzing single cell RNA-seq data	47
3.2. Contextualization, motivation and objectives	50
3.3. Materials and methods	54
3.3.1. Workflow description	54
3.3.2. Literature screening	56
3.3.3. Standardization of gene and group nomenclature	57
3.3.4. Quality control filtering	57
3.3.5. Normalization	59
3.3.6. Highly variable gene selection	61
3.3.7. Dimensionality reduction	61
3.3.8. Exploratory analysis of sources of variability	63
3.3.9. Clustering	64
3.3.10. Cell type annotation	65
3.3.11. Biological inference approaches	66
3.3.11.1. Comparisons	66
3.3.11.2. Differential gene expression analysis	69
3.3.11.3. Over-representation analysis	69
3.3.11.4. Protein-protein interaction analysis	70
3.3.11.5. Signaling pathway activation analysis	71
3.3.11.6. Cell-cell communication analysis	73
3.3.12. Web tool	75
3.4. Results	75
3.4.1. Identification of suitable datasets through literature screening	75
3.4.2. Computational data processing: from quality control to cell type annotation	78
3.4.3. Atlas of sex differences in secondary progressive MS post-mortem brain tissue	81
3.4.3.1. Sex differential alterations in the astrocyte-microglia-neuron triad implicate synaptic components and stress responses	84
3.4.3.2. Sex differential alterations in secondary progressive MS post-mortem brain tissue also affect lipid metabolism and myelin recovery	87
3.4.4. Atlas of sex differences in relapsing-remitting MS peripheral blood mononuclear cells	90

3.4.4.1. <i>Intersection analysis reveals an immune signature core in relapsing-remitting MS females with the implication of the AP-1 transcription factor</i>	92
3.4.4.2. <i>The adaptive immune response in relapsing-remitting MS males exhibits exacerbated mitochondrial dynamics compared to females</i>	93
3.4.5. Atlas of sex differences in primary progressive MS peripheral blood mononuclear cells	93
3.4.5.1. <i>Marked sex differences in CD8+ T cells describe predominant cytolysis in males and homeostatic processes in females</i>	95
3.4.6. Sex differences in immune system status cluster relapsing-remitting MS and primary progressive MS cell types	96
3.4.7. Sex differential viral responses and antigen presentation by MS subtype.....	98
3.4.8. Findings recapitulation and web platform	100
3.5. Discussion	101
4. STUDY II: Integrative analysis to identify sex-differential gut microbiota signatures in multiple sclerosis	107
4.1. Introduction	109
4.1.1. Definitions and considerations of microbial-related terminology.....	109
4.1.2. Dynamics in microbial communities	110
4.1.3. General overview of the human gut microbiota	111
4.1.4. Host modulators in the human gut microbiota.....	112
4.1.5. Impact of diet and transit time	113
4.1.6. Definition of enterotypes.....	115
4.1.7. Gut microbiota states	116
4.1.8. Sex influences the gut microbiota.....	119
4.1.8.1. <i>Gastrointestinal tract microbial composition.</i>	119
4.1.8.2. <i>Immune system interactions</i>	120
4.1.8.3. <i>Gut-brain axis</i>	120
4.1.9. Inherent characteristics of 16S metagenomic data	122
4.1.10. Bioinformatic strategies for analyzing 16S data.....	123
4.2. Contextualization, motivation and objectives	124
4.3. Materials and methods	128
4.3.1. Workflow description	128
4.3.2. Systematic review.....	130
4.3.3. Standardization of metadata nomenclature.....	131
4.3.4. Processing of raw sequencing reads	133

4.3.5. Quantification of amplicon sequence variants.....	135
4.3.6. Phylogenetic annotation.....	136
4.3.7. Filtering criteria at sample level	137
4.3.8. Alpha diversity metric.....	138
4.3.9. Beta diversity metric	138
4.3.10. dbRDA analysis	139
4.3.11. Microbial community typing	141
4.3.12. Statistical tests.....	142
4.3.12.1. χ^2 Goodness of fit.....	142
4.3.12.2. Wilcoxon rank-sum test	143
4.3.12.3. Kruskal-Wallis and post hoc Dunn test	144
4.3.12.4. Spearman correlation.....	144
4.3.13. Identification of differential abundance patterns by dataset considering the condition and sex of the individuals	146
4.3.13.1. Filtering of low-abundance genera	146
4.3.13.2. Normalization.....	146
4.3.13.3. Comparisons	147
4.3.13.4. Differential abundance analysis.....	148
4.3.14. Meta-analysis	149
4.3.15. Web tool.....	151
4.4. Results.....	151
4.4.1. Identification of suitable datasets through literature screening.....	152
4.4.2. Computational data processing.....	156
4.4.3. Assessment of dataset heterogeneity for meta-analysis inclusion.....	159
4.4.4. Individual analysis by dataset	167
4.4.4.1. Within-dataset variability characterization.....	167
4.4.4.2. Individual differential abundance results.....	168
4.4.5. Meta-analysis.....	174
4.4.6. Computational validation.....	180
4.4.6.1. Variability characterization	180
4.4.6.2. Validated taxa	184
4.4.7. Association with MS features	184
4.4.8. Web platform.....	188
4.5. Discussion	189

5. STUDY III: Unveiling common transcriptomic features between melanoma brain metastases and neurodegenerative diseases	195
5.1. Introduction	197
5.1.1. Neurodegenerative diseases share molecular mechanisms	197
5.1.2. The brain as a metastatic niche.....	200
5.1.3. Molecular features of melanoma brain metastasis	203
5.2. Contextualization, motivation and objectives	205
5.3. Materials and Methods	207
5.3.1. Workflow description	207
5.3.2. Data collection	208
5.3.3. Differential gene expression and meta-analyses in neurodegenerative diseases studies.....	209
5.3.4. Intersection analysis	210
5.3.5. Resampling.....	211
5.3.6. Functional signatures of the common transcriptomic features	211
5.3.7. Web tool.....	212
5.4. Results	212
5.4.1. Data collection and differential gene expression analyses by neurodegenerative disease	213
5.4.2. Melanoma brain metastasis-specific genes are often found dysregulated in multiple neurodegenerative diseases	216
5.4.3. Common genetic features between melanoma brain metastasis tumoral signature and neurodegenerative diseases profiles	222
5.4.4. DNAJC6 and ITGA10 as potential key genes in the neurobiology of melanoma brain metastases	225
5.4.5. Web tool.....	225
5.5. Discussion	226
6. General discussion	231
7. Conclusions	239
8. Scientific contributions	243
9. Bibliography	249
10. Annexes	279
10.1. Supplementary material Study I.....	281
10.2. Supplementary material Study II	320
10.3. Supplementary material Study III.....	356